Stephan C. Schürer
教授
Center for Computational Science
University of Miami;Department of Molecular and Cellular Pharmacology, Miller School of Medicine, University of Miami;BD2K-LINCS Data Coordination and Integration Center;Sylvester Comprehensive Cancer Center, Miller School of Medicine, University of Miami
关注
立即认领
分享
关注
立即认领
分享
基本信息
浏览量:186
职业迁徙
个人简介
Research Summary: Research in the Schürer Lab is focused on developing solutions for large-scale integration and modeling of systems biology ‘omics’ and drug protein interaction data to guide translation of disease models into novel functional small molecules with a particular focus on kinases and epigenetic bromodomain reader proteins. Our group applies distributed and parallelized bio- and chemoinformatics tools and builds modeling pipelines to understand drug mechanism of action, –specificity, –promiscuity and –polypharmacology.
In several focused as well as larger-scale projects, we develop formal ontologies (e.g. BioAssay Ontology, Drug Target Ontology), data standards, and end-user multi-tier software applications.
To physically make and test the most promising small molecules, we develop computationally-optimized synthetic routes and apply parallel synthesis technologies to synthesize small compound libraries.
Together these capabilities enable efficient data-driven prioritization of novel drug target hypotheses, identification of precision drug combinations, and the development of novel small molecule tool compounds as starting points for drug discovery projects.
Our group has many drug discovery collaborations ranging from cancer to neurological disorders.
In several focused as well as larger-scale projects, we develop formal ontologies (e.g. BioAssay Ontology, Drug Target Ontology), data standards, and end-user multi-tier software applications.
To physically make and test the most promising small molecules, we develop computationally-optimized synthetic routes and apply parallel synthesis technologies to synthesize small compound libraries.
Together these capabilities enable efficient data-driven prioritization of novel drug target hypotheses, identification of precision drug combinations, and the development of novel small molecule tool compounds as starting points for drug discovery projects.
Our group has many drug discovery collaborations ranging from cancer to neurological disorders.
研究兴趣
论文共 246 篇作者统计合作学者相似作者
按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
Drug Discovery Todayno. 5 (2024): 103953-103953
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCESno. 5 (2024): 2538
Hidehiro Itonaga,Adnan K Mookhtiar,Sarah M Greenblatt, Fan Liu,Concepcion Martinez,Daniel Bilbao, Masai Rains,Pierre-Jacques Hamard,Jun Sun,Afoma C Umeano,Stephanie Duffort,Chuan Chen,
Ayaaz Amirali,Kristina M. Babler, Mark E. Sharkey,Cynthia C. Beaver, Melinda M. Boone,Samuel Comerford,Daniel Cooper, Benjamin B. Currall,Kenneth W. Goodman,George S. Grills,Erin Kobetz,Naresh Kumar,
SCIENCE OF THE TOTAL ENVIRONMENT (2024): 170452-170452
Drug discovery todayno. 1 (2023): 103847-103847
Journal of biomolecular techniques : JBTno. 4 (2023)
CANCER RESEARCH COMMUNICATIONSno. 8 (2023): 1688-1688
NUCLEIC ACIDS RESEARCH (2023)
加载更多
作者统计
合作学者
合作机构
D-Core
- 合作者
- 学生
- 导师
数据免责声明
页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果,我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问,可以通过电子邮件方式联系我们:report@aminer.cn